MKI67 and neuroendocrine carcinoma: In that regard, the NORDIC NEC study was a landmark paper, demonstrating that patients suffering from a NEN with a Ki-67 < 55% are less likely to experience a response to platinum-based chemotherapy than those with Ki-67 index > 55% (Sorbye et al. 2013).